Central Pacific Bank Trust Division Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Central Pacific Bank Trust Division significantly increased its stock holdings in Regeneron Pharmaceuticals by 70.9% during the second quarter, reaching a total value of $607,000.
• Regeneron Pharmaceuticals reported $12.89 earnings per share in its latest quarter, surpassing estimates and demonstrating a 3.6% year-over-year revenue increase.
• The company declared a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6% and a low dividend payout ratio of 8.87%.

Central Pacific Bank Trust Division increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 70.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,157 shares of the biopharmaceutical company's stock after acquiring an additional 480 shares during the quarter. Central Pacific Bank Trust Division's holdings in Regeneron Pharmaceuticals were worth $607,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the period. Activest Wealth Management lifted its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth $27,000. Finally, Saudi Central Bank purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $560.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,170.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business has a fifty day moving average price of $564.61 and a 200-day moving average price of $578.77. The company has a market capitalization of $59.35 billion, a PE ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the company earned $11.56 earnings per share. The company's revenue was up 3.6% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

A number of analysts recently commented on REGN shares. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Citigroup reissued a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Jefferies Financial Group raised their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.